Stroke Prevention in Atrial Fibrillation

Introduction to Stroke Prevention

The European Society of Cardiology recommends oral anticoagulation with a direct oral anticoagulant (DOAC) as first-line therapy, combined with aggressive blood pressure control to target <130/80 mmHg, for patients with atrial fibrillation and hypertension 1, 2

Patients with atrial fibrillation and hypertension automatically have a CHA₂DS₂-VASc score ≥1, making them candidates for anticoagulation rather than aspirin alone, according to the European Heart Journal 3
The presence of both age >60 years and hypertension eliminates the "low risk" category entirely, as stated by the American Heart Association 4

The European Society of Cardiology recommends initiating a DOAC (rivaroxaban, apixaban, dabigatran, or edoxaban) as the preferred anticoagulant over warfarin, due to superior safety profiles and comparable or better efficacy 1, 2, 3
DOACs reduce stroke risk by 60-68% compared to no treatment, as reported by the European Heart Journal 3
Aspirin monotherapy is no longer recommended for stroke prevention in atrial fibrillation, as it provides minimal efficacy (only 20-30% risk reduction) with substantial bleeding risk, according to the American College of Chest Physicians 3, 5

The European Society of Cardiology recommends achieving and maintaining optimal blood pressure control with target <130/80 mmHg using ACE inhibitors or ARBs as first-line agents, for patients with atrial fibrillation and hypertension 1, 2
Uncontrolled hypertension must be addressed before initiating anticoagulation to minimize bleeding risk, particularly intracranial hemorrhage, as stated by the American Heart Association 3, 6
Blood pressure control is critically important in atrial fibrillation patients on anticoagulation—it reduces both ischemic stroke risk and the risk of intracranial hemorrhage, according to the American Heart Association 6, 4

The European Society of Cardiology recommends maintaining normal body weight (BMI 20-25 kg/m²) through dietary modifications and regular exercise, for patients with atrial fibrillation 1, 2
Prescribing 150-300 minutes per week of moderate-intensity aerobic physical activity is recommended, as stated by the European Society of Cardiology 1, 2
Screening for and aggressively managing diabetes, if present, is recommended, according to the European Society of Cardiology 1, 2
Treating obstructive sleep apnea, if suspected, is recommended, as reported by the American College of Chest Physicians 5

Assessing renal function, electrolytes, and thyroid function at baseline and periodically is recommended, according to the European Heart Journal 3
Regular follow-up to assess bleeding risk factors and ensure adherence is recommended, as stated by the American College of Chest Physicians 5
Adding antiplatelet therapy (aspirin or clopidogrel) is not recommended unless there is a specific indication, such as recent acute coronary syndrome or stenting, due to increased bleeding risk, according to the European Heart Journal 3

Age alone is never a contraindication to anticoagulation, as the absolute benefit of stroke prevention exceeds bleeding risk in elderly patients when blood pressure is controlled, as stated by the American Heart Association 6, 4
Using aspirin as a substitute for anticoagulation in patients with CHA₂DS₂-VASc ≥1 is outdated practice, according to the European Heart Journal and the American College of Chest Physicians 3, 5

The American Heart Association recommends that older adults with atrial fibrillation and cardiovascular disease should receive oral anticoagulation with warfarin (target INR 2.0-3.0) or a direct oral anticoagulant (DOAC), as this reduces stroke risk by 60-68% compared to no treatment and by 45% compared to aspirin alone 7, 8
Atrial fibrillation confers a 3- to 4-fold increased stroke risk after adjusting for other vascular factors, with approximately 60,000 strokes occurring annually among Americans with this arrhythmia 7

The CHADS₂ scoring system should guide anticoagulation decisions, with points assigned for congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke or TIA 7, 9
The American College of Cardiology recommends the following treatment based on CHADS₂ score:
- Score 0 (1.0%/year stroke risk): Aspirin 75-325 mg daily 7
- Score 1 (1.5%/year stroke risk): Warfarin INR 2-3 OR aspirin 75-325 mg daily 7
- Score ≥2 (2.5-7%/year stroke risk): Warfarin INR 2-3 (Class I recommendation) 7, 9

Warfarin reduces stroke risk by 68% in primary prevention and 62% for combined ischemic and hemorrhagic stroke, with a target INR of 2.0-3.0 for most patients 8, 7, 10
The European Society of Cardiology recommends that dabigatran may be considered in patients over 75 years with additional bleeding risk factors, with a reduced dose of 110 mg twice daily (Class IIb, Level B) 11

Age alone is not a contraindication to anticoagulation, as the absolute benefit of stroke prevention exceeds bleeding risk in the vast majority of elderly patients 10, 11
Modifiable bleeding risk factors to address include blood pressure control, avoiding NSAIDs and unnecessary antiplatelet agents, monitoring renal function, reviewing drug interactions, and ensuring appropriate dosing 11, 12

Heart failure increases stroke risk (relative risk 1.4) and does not contraindicate anticoagulation; rather, it strengthens the indication 13, 14, 7
Coronary artery disease increases stroke risk (relative risk 1.5), and if recent acute coronary syndrome or stenting, triple therapy may be needed temporarily, but duration should be minimized 13, 14, 12
Hypertension increases stroke risk (relative risk 1.6) and must be controlled to reduce both stroke and bleeding risk during anticoagulation 13, 14, 10, 11, 12